Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01087905 · ClinicalTrials.gov registry record · Phase 4
Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines
A Phase 4 study of Smoking Cessation and Smoking, sponsored by University of Wisconsin, Madison.
- Completed
- Registry status
- Phase 4
- Development phase
- 987
- Enrollment target
- 2
- Study locations
NCT01087905 is a Phase 4 study of Smoking Cessation and Smoking that has completed, run by University of Wisconsin, Madison. The registered enrollment target is 987 participants, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (110% higher). The trial reports 2 study locations across 2 states.
The verdict
NCT01087905, a Phase 4 study of Smoking Cessation and Smoking, has completed, sponsored by University of Wisconsin, Madison.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 987 participants
- Enrollment target
- 2
- Study locations
Study Summary
Research shows that smoking cessation is the most significant preventable health behavior change that a person can make to lower cancer risk. In addition, telephone quitlines are an effective, science-based smoking cessation treatment that is universally accessible to smokers in the U.S. However, little research has explored promising approaches that could increase quitline use, improve quit rates, and inform resource allocation for quitline services. The proposed study will test three promising enhancements to the standard quitline treatment that typically consists of counseling and, possibly 2 weeks of a NRT medication. These enhancements are: 1) combination nicotine replacement therapy as recommended by the United States Public Health Service Clinical Practice Guideline on Treating Tobacco Use and Dependence; 2) extended duration of cessation medication use; and 3) an innovative counseling addition - cognitive medication adherence counseling - to optimize adherence to cessation medication. In addition, the cost-effectiveness of each intervention will be calculated. The findings of the proposed research have broad potential application and relevance to state quitlines, quitline service providers, and other purchasers of quitline services such as employers and insurers. Additionally, the study findings can potentially inform other telephone health behavior counseling programs.
Conditions Studied
Interventions
- DRUG Nicotine gum
- DRUG Nicotine patch
- BEHAVIORAL CMAC
Study Locations (2)
Washington
- Wisconsin Tobacco Quit Line (service provided by Free & Clear, Inc.) - Seattle
Wisconsin
- University of Wisconsin Center for Tobacco Research and Intervention - Madison
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 987 participants |
| Start Date | 2010-04 |
| Est. Completion | 2011-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01087905
The ClinicalTrials.gov registry entry for NCT01087905 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 987 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 469-participant average among 188 other Smoking Cessation trials with a reported enrollment target (110% higher). The listed sponsor is University of Wisconsin, Madison, which has 1,039 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Smoking Cessation appearing as the primary indexed condition, and to 3 interventions - of which Nicotine gum is the first listed.
NCT01087905 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Washington, Wisconsin.
Frequently Asked Questions
What is clinical trial NCT01087905 about?
NCT01087905 is a clinical study titled "Improving the Population-Wide Effectiveness of U.S. Tobacco Cessation Quitlines". Research shows that smoking cessation is the most significant preventable health behavior change that a person can make to lower cancer risk. In addition, telephone quitlines are an effective, science-based smoking cessation treatment that is universally accessible to smokers in the U.S. However, li...
What is the current status of trial NCT01087905?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 987 participants. The study started on 2010-04. Estimated completion is 2011-11.
What conditions does trial NCT01087905 study?
This clinical trial studies the following conditions: Smoking Cessation, Smoking.
What interventions are being tested in trial NCT01087905?
The interventions under investigation include: Nicotine gum (DRUG), Nicotine patch (DRUG), CMAC (BEHAVIORAL).
Who is sponsoring clinical trial NCT01087905?
This trial is sponsored by University of Wisconsin, Madison, which has 1,039 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01087905 being conducted?
This trial has 2 study locations across Washington, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking Cessation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Modifying Progesterone and Estradiol Levels to Prevent Postpartum Cigarette Smoking Relapse and Reduce Secondhand Smoke Exposure in Infants and Children
RECRUITING · Phase 4
-
The Options 2 Study
RECRUITING · Phase 4
-
Smoking Cessation Program in the Construction Sector
RECRUITING · Phase 4
-
The Avenues Study: Dual Use Cessation
RECRUITING · Phase 4
-
Using Multiphase Optimization Strategy (MOST) to Optimize a Cost-effective, Sustainable and Scalable Smoking Cessation Package for Smokers in HIV Clinical Care
RECRUITING · Phase 4
-
Implementing Tobacco Treatment in Low Dose CT Lung Cancer Screening Sites
ACTIVE NOT RECRUITING · Phase 4
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.